Posted by Michael Wonder on 18 Mar 2026
FluoGuide receives FDA fast track designation for FG001 in high grade glioma
18 March 2026 - FluoGuide announces that the US FDA has granted fast track designation to FG001 as an intra-operative imaging agent to guide surgical resection of high grade glioma.
Following the FDA green light on FluoGuide’s IND in January, the Company is in preparation to initiate the planned US Phase 2 registration trial of FG001 in high grade glioma with first patient planned to be enrolled in Q2 this year.
